Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer
—Overall response rates of 12.5% are observed in the enobosarm group in a heavily pretreated…
Digital Heroes Marks 2,000 Brand Launches Across 55 Countries Through Global Technology Services
ANT Law Firm Strengthens Its Orlando Legal Services for Car Accident, Slip and Fall, and Wrongful Death Victims
LumenIsle Launches Australian Market Service Review and International Video Traceability Initiative for Memorial Diamonds
HiBob Named Best HR Management Software in the UK for 2026
Ionik Announces 30-Day Extension of Senior Debt Facility